Abstract
Nanoparticle synthesis has elicited intense interest within the past decade. Nanoparticle size ranges from 100 to 500 nm and can be solid particles or colloidal in nature. When this particles size or its surface characteristics are manipulated, they can be developed into imaging agents, encasing therapeutic, or a smart system for use in diverse application. Drug formulations from nanoparticle-based materials have opened up a novel field of research in the treatment and management of challenging diseases. This system can be designed to deliver drug to target tissues as well as provide the controlled release of these drugs. The continual drug delivery to target tissues results in declining drug-related toxicity as well as increasing patient’s compliance with lower doing index. Some illness in which nanotechnology has made positive impact includes AIDS, cancer, and several other related diseases.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
References
Farokhzad OC, Langer R (2009) Impact of nanotechnology on drug delivery. ACS Nano 3(1):16–20. https://doi.org/10.1021/nn900002m
Emerich DF, Thanos CG (2007) Targeted nanoparticle-based drug delivery and diagnosis. J Drug Target 15(3):163–183
Biswas AK, Islam MR, Choudhury ZS et al (2014) Nanotechnology based approaches in cancer therapeutics. Adv Nat Sci Nanosci Nanotechnol 5:043001
Wicki A, Witzigmann D, Balasubramanian V, Huwyler J (2015) Nanomedicine in cancer therapy: challenges, opportunities, and clinical applications. J Control Release 200:138–157
Vo TN, Kasper FK, Mikos AG (2012) Strategies for controlled delivery of growth factors and cells for bone regeneration. Adv Drug Deliv Rev 64(12):1292–1309
Osakwe O, Rizvi SAA (2016) Social aspects of drug discovery, development and commercialization. Academic, Cambridge, MA
Dadwal A, Baldi A, Narang RK (2018) Nanoparticles as carriers for drug delivery in cancer. J Artif Cells Nanomed Biotechnol 46(S2):295–305. https://doi.org/10.1080/21691401.2018.1457039
Mu Q, Jiang G, Chen L et al (2014) Chemical basis of interactions between engineered nanoparticles and biological systems. Chem Rev 114(15):7740–7781
Prado-Gotor R, Grueso E (2011) A kinetic study of the interaction of DNA with gold nanoparticles: mechanistic aspects of the interaction. Phys Chem Chem Phys 13(4):1479–1489
Park HS, Nam SH, Kim J et al (2016) Clear-cut observation of clearance of sustainable upconverting nanoparticles from lymphatic system of small living mice. Sci Rep 6:27407
Alexis F, Pridgen E, Molnar LK, Farokhzad OC (2008) Factors affecting the clearance and biodistribution of polymeric nanoparticles. Mol Pharm 5(4):505–515
Liu R, Kay BK, Jiang S, Chen S (2009) Nanoparticle delivery: targeting and nonspecific binding. MRS Bull 34(6):432–440
Friedman AD, Claypool SE, Liu R (2013) The smart targeting of nanoparticles. Curr Pharm Des 19(35):6315–6329
Pramanik AK, Siddikuzzaman, Palanimuthu D et al (2016) Biotin decorated gold nanoparticles for targeted delivery of a smart-linked anticancer active copper complex: in vitro and in vivo studies. Bioconjug Chem 27(12):2874–2885
Kelly C, Jefferies C, Cryan S-A (2011) Targeted liposomal drug delivery to monocytes and macrophages. J Drug Deliv 2011:727241. https://doi.org/10.1155/2011/727241
Pattni BS, Chupin VV, Torchilin VP et al (2015) New developments in liposomal drug delivery. Chem Rev 115(19):10938–10966
Rizzo LY, Theek B, Storm G et al (2013) Recent progress in nanomedicine: therapeutic, diagnostic and theranostic applications. Curr Opin Biotechnol 24(6):1159–1166
Shrivastava S, Dash D (2009) Applying nanotechnology to human health: revolution in biomedical sciences. J Nanotechnol 2009:1–14. https://doi.org/10.1155/2009/184702
Sadrieh N, Miller TJ (2006) Nanotechnology: regulatory perspective for drug development in cancer therapeutics. In: Amiji MM (ed) Nanotechnology for cancer therapy. CRC Press, Boca Raton, pp 139–156
Rivera Gil P, Huhn D, Del Mercato LL et al (2010) Nanopharmacy: inorganic nanoscale devices as vectors and active compounds. Pharmacol Res 62(2):115–125
Weissig V, Pettinger TK, Murdock N (2014) Nanopharmaceuticals (Part 1): products on the market. Int J Nanomedicine 9:4357–4373
Öztürk-Atar K, Eroglu H, Gürsoy RN, Çalis S (2019) Current advances in nanopharmaceuticals. J Nanosci Nanotechnol 19:3686–3705
Zolnik BS, Sadrieh N (2009) Regulatory perspective on the importance of ADME assessment of nanoscale material containing drugs. Adv Drug Deliv Rev 61(6):422–427
Mostafalou S, Mohammadi H, Ramazani A, Abdollahi M (2013) Different biokinetics of nanomedicines linking to their toxicity; an overview. Daru 21(1):1
Berkner S, Schwirn K, Voelker D (2016) Nanopharmaceuticals: tiny challenges for the environmental risk assessment of pharmaceuticals. Environ Toxicol Chem 35(4):780–787
Wang RB, Billone PS, Mullett WM (2013) Nanomedicine in action: an overview of cancer nanomedicine on the market and in clinical trials. J Nanomater 2013:1–12
Jeevanandam J, Barhoum A, Chan YS et al (2018) Review on nanoparticles and nanostructured materials: history, sources, toxicity and regulations. Beilstein J Nanotechnol 9:1050–1074
Ogris M, Oupicky D (2013) Nanotechnology for nucleic acid delivery. Humana Press, New York
Bangham AD, Standish MM, Watkins JC (1965) Diffusion of univalent ions across the lamellae of swollen phospholipids. J Mol Biol 13(1):238–252
Puri A, Kramer-Marek G, Campbell-Massa R (2008) HER2-specific affibody-conjugated thermosensitive liposomes (affisomes) for improved delivery of anticancer agents. J Liposome Res 18(4):293–307
Jain S, Tiwary AK, Sapra B, Jain N (2007) Formulation and evaluation of ethosomes for transdermal delivery of lamivudine. AAPS PharmSciTech 8(4):249–257
Dubey V, Mishra D, Nahar M et al (2010) Enhanced transdermal delivery of an anti-HIV agent via ethanolic liposomes. Nanomedicine 6(4):590–596
Suk JS, Xu Q, Kim N et al (2016) PEGylation as a strategy for improving nanoparticle-based drug and gene delivery. Adv Drug Deliv Rev 99:28–51
Milla P, Dosio F, Cattel L (2012) PEGylation of proteins and liposomes: a powerful and flexible strategy to improve the drug delivery. Curr Drug Metab 13:105–119
Petrilli R, Eloy JO, Lee RJ et al (2018) Preparation of immunoliposomes by direct coupling of antibodies based on a thioether bond. Methods Mol Biol 1674:229–237
Brewer E, Coleman J, Lowman A (2011) Emerging technologies of polymeric nanoparticles in cancer drug delivery. J Nanomater 2011:1–10
Owens DE III, Peppas NA (2006) Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles. Int J Pharm 307(1):93–102
Pandey R, Sharma A, Zahoor A et al (2003) Poly(DL-lactide-co-glycolide) nanoparticle-based inhalable sustained drug delivery system for experimental tuberculosis. J Antimicrob Chemother 52:981–986
Seong JH, Lee KM, Kim ST et al (2006) Polyethylenimine based antisense oligodeoxynucleotides of IL-4 suppresses the production of IL-4 in a murine model of airway inflammation. J Gene Med 8:314–323
Azarmi S, Tao X, Chen H (2006) Formulation and cytotoxicity of doxorubicin nanoparticles carried by dry powder aerosol particles. Int J Pharm 319:155–161
Valls R, Vega E, Garcia ML et al (2008) Transcorneal permeation in a corneal device of non-steroidal anti-inflammatory drugs in drug delivery systems. Open Med Chem J 2:66–71
Kimura S, Egashira K, Chen L (2009) Nanoparticle-mediated delivery of nuclear factor κB decoy into lungs ameliorates monocrotaline-induced pulmonary arterial hypertension. Hypertension 53(5):877–883
Yang X, Zhu B, Dong T et al (2008) Interactions between an anticancer drug and polymeric micelles based on biodegradable polyesters. Macromol Biosci 8(12):1116–1125
Sun T, Zhang YS, Pang B et al (2014) Engineered nanoparticles for drug delivery in cancer therapy. Angew Chem Int Ed Eng 53:12320–12364
Lee CC, Mackay JA, Frechet JM et al (2005) Designing dendrimers for biological applications. Nat Biotechnol 23:1517–1526
Omidi Y, Barar J (2009) Induction of human alveolar epithelial cell growth factor receptors by dendrimeric nanostructures. Int J Toxicol 28:113–122
Hamidi A, Sharifi S, Davaran S et al (2012) Novel aldehyde terminated dendrimers; synthesis and cytotoxicity assay. Bioimpacts 2:97–103
Nourazarian AR, Pashaei-Asl R, Omidi Y et al (2012) c-Src antisense complexed with PAMAM denderimes decreases of c-Src expression and EGFR-dependent downstream genes in the human HT-29 colon cancer cell line. Asian Pac J Cancer Prev 13:2235–2240
Madaan K, Kumar S, Poonia N et al (2014) Dendrimers in drug delivery and targeting: drug-dendrimer interactions and toxicity issues. J Pharm Bioallied Sci 6:139–150
Palmerston Mendes L, Pan J, Torchilin VP (2017) Dendrimers as nanocarriers for nucleic acid and drug delivery in cancer therapy. Molecules 22:1401
Gillies ER, Jonsson TB, Frechet JM (2004) Stimuli-responsive supramolecular assemblies of linear-dendritic copolymers. J Am Chem Soc 126:11936–11943
Kalomiraki M, Thermos K, Chaniotakis NA (2016) Dendrimers as tunable vectors of drug delivery systems and biomedical and ocular applications. Int J Nanomedicine 11:1–12
Yoon AR, Kasala D, Li Y et al (2016) Antitumor effect and safety profile of systemically delivered oncolytic adenovirus complexed with EGFR-targeted PAMAM-based dendrimer in orthotopic lung tumor model. J Control Release 231:2–16
Svenson S (2009) Dendrimers as versatile platform in drug delivery applications. Eur J Pharm Biopharm 71:445–462
Heidari Majd M, Asgari D, Barar J et al (2013) Tamoxifen loaded folic acid armed PEGylated magnetic nanoparticles for targeted imaging and therapy of cancer. Colloids Surf B: Biointerfaces 106:117–125
Leung SL, Zha Z, Cohn C et al (2014) Anti-EGFR antibody conjugated organic-inorganic hybrid lipid nanovesicles selectively target tumor cells. Colloids Surf B: Biointerfaces 121:141–149
Barar J, Kafil V, Majd MH et al (2015) Multifunctional mitoxantrone-conjugated magnetic nanosystem for targeted therapy of folate receptor-overexpressing malignant cells. J Nanobiotechnol 13:26
Azhdarzadeh M, Atyabi F, Saei AA et al (2016) Theranostic MUC-1 aptamer targeted gold coated superparamagnetic iron oxide nanoparticles for magnetic resonance imaging and photothermal therapy of colon cancer. Colloids Surf B: Biointerfaces 143:224–232
Senapati S, Mahanta AK, Kumar S et al (2018) Controlled drug delivery vehicles for cancer treatment and their performance. Signal Transduct Target Ther 3:7
Bawarski WE, Chidlowsky E, Bharali DJ et al (2008) Emerging nanopharmaceuticals. Nanomedicine 4:273–282
Mu Q, Yu J, Mcconnachie LA et al (2018) Translation of combination nanodrugs into nanomedicines: lessons learned and future outlook. J Drug Target 26:435–447
Michalet X, Pinaud F, Bentolila L et al (2005) Quantum dots for live cells, in vivo imaging, and diagnostics. Science 307(5709):538–544
El-Sayed IH, Huang X, El-Sayed MA (2006) Selective laser photo-thermal therapy of epithelial carcinoma using anti-EGFR antibody conjugated gold nanoparticles. Cancer Lett 239(1):129–135
Hild W, Breunig M, Gopferich A (2008) Quantum dots–nano-sized probes for the exploration of cellular and intracellular targeting. Eur J Pharm Biopharm 68(2):153–168
Barathmanikanth S, Kalishwaralal K, Sriram M et al (2010) Anti-oxidant effect of gold nanoparticles restrains hyperglycemic conditions in diabetic mice. J Nanobiotechnol 8(1):16
Liao YH, Chang YJ, Yoshiike Y et al (2012) Negatively charged gold nanoparticles inhibit Alzheimer’s amyloid-β fibrillization, induce fibril dissociation, and mitigate neurotoxicity. Small 8(23):3631–3639
Leonavičienė L, Kirdaitė G, Bradūnaitė R et al (2012) Effect of gold nanoparticles in the treatment of established collagen arthritis in rats. Medicina (Kaunas) 48(2):91–101
Spivak MY, Bubnov RV, Yemets IM et al (2013) Development and testing of gold nanoparticles for drug delivery and treatment of heart failure: a theranostic potential for PPP cardiology. EPMA J 4(1):20
Cha C, Shin SR, Annabi N et al (2013) Carbon based nanomaterials: multi-functional materials for biomedical engineering. ACS Nano 7:2891–2897
Bianco A, Kostarelos K, Partidos CD, Prato M (2005) Biomedical applications of functionalised carbon nanotubes. Chem Commun 7:571–577
Roldo M (2016) Carbon nanotubes in drug delivery: just a carrier? Ther Deliv 7:55–57
Harrison BS, Atala A (2007) Carbon nanotube applications for tissue engineering. Biomaterials 28:344–353
Yang S-T, Luo J, Zhou Q, Wang H (2012) Pharmacokinetics, metabolism and toxicity of carbon nanotubes for biomedical purposes. Theranostics 2:271–282
Chaudhuri P, Harfouche R, Soni S et al (2010) Shape effect of carbon nanovectors on angiogenesis. ACS Nano 4:574–582
Kolosnjaj J, Szwarc H, Moussa F (2007) Toxicity studies of fullerenes and derivatives. In: Chan WCW (ed) Bio-applications of nanoparticles. Springer, New York, pp 168–180
Liu W, Speranza G (2019) Functionalization of carbon nanomaterials for biomedical applications. C J Carbon Res 5:72. https://doi.org/10.3390/c5040072
Pisanic TR II, Zhang Y, Wang TH (2014) Quantum dots in diagnostics and detection: principles and paradigms. Analyst 139(12):2968–2981
Marchesan S, Prato M (2013) Nanomaterials for (nano)medicine. ACS Med Chem Lett 4(2):147–149
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2021 Springer Nature Switzerland AG
About this entry
Cite this entry
Islam, S. et al. (2021). Nanomaterials: Applications in Biomedicine and Biotechnology. In: Kharissova, O.V., Torres-Martínez, L.M., Kharisov, B.I. (eds) Handbook of Nanomaterials and Nanocomposites for Energy and Environmental Applications. Springer, Cham. https://doi.org/10.1007/978-3-030-36268-3_4
Download citation
DOI: https://doi.org/10.1007/978-3-030-36268-3_4
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-36267-6
Online ISBN: 978-3-030-36268-3
eBook Packages: Chemistry and Materials ScienceReference Module Physical and Materials ScienceReference Module Chemistry, Materials and Physics